Posted by Michael Wonder on 27 Jun 2023
Xigduo XR approved in China for adults with type 2 diabetes
27 June 2023 - Approval makes Xigduo XR the only once daily fixed-dose combination of an SGLT2 inhibitor and metformin hydrochloride extended release in China.
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control.
